
Noema Pharma AG closes Series B financing
CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Abionyx Pharma announces success in fighting sepsis-triggered AKI
After AM-Pharma’s human recombinant alkaline phosphatase, ilofotase alfa, missed the endpoint of improving overall survival in patients with...

Henkel buys FDCA from Avantium NV
From next year, Henkel will buy FDCA to bring environmentally friendly high-performance polyurethane adhesives for electronic applications to market....

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...